


06/09/04

1FW



Express Mail Label No.
EV 416452640 US

PHA 4310 (3321/1/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Mark L. Boys et al

Serial No. 10/743,354

Filed December 22, 2003

Confirmation No. 9317

For HETEROARYLALKANOIC ACIDS AS INTEGRIN
RECEPTOR ANTAGONISTS DERIVATIVES

June 8, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.


This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it is being filed prior to the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the date of mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account No. 19-1345.

I certify that each item contained in this statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Respectfully submitted,

Kathleen M. Petrillo, Reg. No. 35,076
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KMP/CDS/cms

PTO/SB/08A			Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)			Application Number	10/743,354
			Filing Date	December 22, 2003
			Confirmation Number	9317
			First Named Inventor	Mark L. Boys et al
			Group Art Unit	
			Examiner Name	
Sheet 1	of 1	Attorney Docket No.	PHA 4310 (3321/1/US)	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	40.	WO	98/18461		Merck & Co., Inc.	05/07/1998	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	41.	International Search Report for PCT/US03/40629, dated 05/07/2004	
	42.	PLOUVIER et al., "Antitumor Combilexin. A Thiazole-Containing Analogue of Netropsin Linked to an Acridine Chromophore", Bioconjugate Chem, 1994, 5(5), 475-481	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.